Praveen K. Bommareddy

2.9k total citations · 1 hit paper
44 papers, 1.7k citations indexed

About

Praveen K. Bommareddy is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Praveen K. Bommareddy has authored 44 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 29 papers in Oncology and 19 papers in Immunology. Recurrent topics in Praveen K. Bommareddy's work include Virus-based gene therapy research (33 papers), CAR-T cell therapy research (27 papers) and Immunotherapy and Immune Responses (18 papers). Praveen K. Bommareddy is often cited by papers focused on Virus-based gene therapy research (33 papers), CAR-T cell therapy research (27 papers) and Immunotherapy and Immune Responses (18 papers). Praveen K. Bommareddy collaborates with scholars based in United States, United Kingdom and France. Praveen K. Bommareddy's co-authors include Howard L. Kaufman, Megha Shettigar, Andrew Zloza, Anand Patel, Samuel D. Rabkin, Ann W. Silk, Dipongkor Saha, Hong-My Nguyen, Kevin J. Harrington and Sachin R. Jhawar and has published in prestigious journals such as Neuron, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Praveen K. Bommareddy

43 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrating oncolytic viruses in combination cancer immunotherapy

2018 518 citations Praveen K. Bommareddy, Megha Shettigar et al. Nature reviews. Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Praveen K. Bommareddy United States	16	1.1k	963	631	545	269	44	1.7k
Elizabeth J. Ilett United Kingdom	24	1.2k 1.1×	1.2k 1.3×	541 0.9×	602 1.1×	141 0.5×	38	1.9k
Dipongkor Saha United States	24	804 0.8×	887 0.9×	457 0.7×	409 0.8×	195 0.7×	47	1.7k
Brad E. Hoffman United States	25	552 0.5×	972 1.0×	965 1.5×	368 0.7×	183 0.7×	35	2.0k
Barbara Leuchs Germany	22	470 0.4×	1.1k 1.2×	942 1.5×	186 0.3×	161 0.6×	51	1.8k
Heung Chong United Kingdom	18	537 0.5×	758 0.8×	874 1.4×	498 0.9×	175 0.7×	36	1.5k
Johanna K. Kaufmann Germany	13	551 0.5×	497 0.5×	451 0.7×	325 0.6×	163 0.6×	26	1.0k
W. Jay Ramsey United States	16	587 0.5×	1.2k 1.3×	1.3k 2.0×	228 0.4×	163 0.6×	34	1.8k
David‐Alexandre Gross France	23	458 0.4×	529 0.5×	898 1.4×	911 1.7×	143 0.5×	41	1.7k
Dinko Valerio Netherlands	26	611 0.6×	1.1k 1.1×	1.1k 1.8×	241 0.4×	181 0.7×	56	1.9k
Juan J. Rojas Spain	17	575 0.5×	731 0.8×	455 0.7×	170 0.3×	63 0.2×	23	967

Countries citing papers authored by Praveen K. Bommareddy

Since Specialization

Citations

This map shows the geographic impact of Praveen K. Bommareddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Praveen K. Bommareddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Praveen K. Bommareddy more than expected).

Fields of papers citing papers by Praveen K. Bommareddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Praveen K. Bommareddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Praveen K. Bommareddy. The network helps show where Praveen K. Bommareddy may publish in the future.

Co-authorship network of co-authors of Praveen K. Bommareddy

This figure shows the co-authorship network connecting the top 25 collaborators of Praveen K. Bommareddy. A scholar is included among the top collaborators of Praveen K. Bommareddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Praveen K. Bommareddy. Praveen K. Bommareddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bommareddy, Praveen K., Hiroaki Wakimoto, Robert L. Martuza, et al.. (2024). Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for ImmunoTherapy of Cancer. 12(4). e008880–e008880. 25 indexed citations

Migden, Michael R., Wanxing Chai‐Ho, Gregory A. Daniels, et al.. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). SHILAP Revista de lepidopterología. A874–A874. 1 indexed citations

Sacco, Joseph J., Kevin J. Harrington, Anna Olsson‐Brown, et al.. (2023). Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9527–9527. 4 indexed citations

Khushalani, Nikhil I., Kevin J. Harrington, Alan Melcher, Praveen K. Bommareddy, & Dmitriy Zamarin. (2023). Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment. Molecular Therapy — Oncolytics. 31. 100729–100729. 10 indexed citations

Milhem, Mohammed, Ari M. Vanderwalde, Tawnya L. Bowles, et al.. (2022). Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. Journal of Clinical Oncology. 40(16_suppl). 9553–9553. 13 indexed citations

Haydon, Andrew, Muhammad Alamgeer, Daniel Brungs, et al.. (2021). 1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]. Annals of Oncology. 32. S904–S904. 2 indexed citations

Roulstone, Victoria, Joan Kyula, Suzanne Thomas, et al.. (2021). Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy. Cancer Research. 81(13_Supplement). 1917–1917. 1 indexed citations

Nguyen, Hong-My, Praveen K. Bommareddy, Ann W. Silk, & Dipongkor Saha. (2021). Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Seminars in Cancer Biology. 86(Pt 3). 971–980. 34 indexed citations

Poillet-Perez, Laura, Daniel W. Sharp, Yang Yang, et al.. (2020). Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. Nature Cancer. 1(9). 923–934. 78 indexed citations

10.

Silk, Ann W., Howard L. Kaufman, Brendan D. Curti, et al.. (2020). High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology. 9. 1483–1483. 9 indexed citations

11.

Middleton, Mark R., Francesca Aroldi, Joseph J. Sacco, et al.. (2020). An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology. 38(15_suppl). e22050–e22050. 16 indexed citations

12.

Aroldi, Francesca, Joseph J. Sacco, Kevin J. Harrington, et al.. (2020). 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. SHILAP Revista de lepidopterología. A256.2–A257. 6 indexed citations

13.

Bommareddy, Praveen K., Samuel D. Rabkin, & Howard L. Kaufman. (2019). Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. OncoImmunology. 8(4). e1571390–e1571390. 1 indexed citations

14.

Bommareddy, Praveen K., Andrew Zloza, Samuel D. Rabkin, & Howard L. Kaufman. (2019). Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. OncoImmunology. 8(7). e1591875–e1591875. 97 indexed citations

15.

Thomas, Suzanne, Victoria Roulstone, Joan Kyula, et al.. (2019). Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. Journal for ImmunoTherapy of Cancer. 7(1). 214–214. 119 indexed citations

16.

Bommareddy, Praveen K., Devin B. Lowe, Howard L. Kaufman, Samuel D. Rabkin, & Dipongkor Saha. (2019). Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. Journal of Biological Methods. 6(2). 1–1. 7 indexed citations

17.

Bommareddy, Praveen K., Megha Shettigar, & Howard L. Kaufman. (2018). Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy. Nature reviews. Immunology. 18(8). 536–536. 9 indexed citations

18.

Jhawar, Sachin R., Praveen K. Bommareddy, Frederick J. Kohlhapp, et al.. (2017). Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. Frontiers in Oncology. 7. 202–202. 130 indexed citations

19.

Bommareddy, Praveen K., et al.. (2016). Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. American Journal of Clinical Dermatology. 18(1). 1–15. 235 indexed citations

20.

Mende, Michael, Emily V. Fletcher, Joseph P. Pierce, et al.. (2016). Sensory-Derived Glutamate Regulates Presynaptic Inhibitory Terminals in Mouse Spinal Cord. Neuron. 90(6). 1189–1202. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact